GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alteogen Inc (XKRX:196170) » Definitions » Institutional Ownership

Alteogen (XKRX:196170) Institutional Ownership : 12.77% (As of Mar. 25, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Alteogen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alteogen's institutional ownership is 12.77%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alteogen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alteogen's Float Percentage Of Total Shares Outstanding is 0.00%.


Alteogen Institutional Ownership Historical Data

The historical data trend for Alteogen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alteogen Institutional Ownership Chart

Alteogen Historical Data

The historical data trend for Alteogen can be seen below:

2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28
Institutional Ownership 10.20 12.38 12.43 12.52 12.43 12.59 12.63 12.73 12.72 12.77

Alteogen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Alteogen Business Description

Traded in Other Exchanges
N/A
Address
62, Yuseong-daero 1628beon-gil, Yuseong-gu, Daejeon, KOR, 34054
Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars by partnerships with pharmaceutical companies. It focuses on the areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.

Alteogen Headlines

No Headlines